TY - JOUR
T1 - AMCP Partnership Forum
T2 - Racial health disparities-a closer look at benefit design
AU - Angove, Rebekah
AU - Banks, Angela
AU - Barrington, Christina
AU - Bettarelli, Maribeth
AU - Brixner, Diana
AU - Brown, Kathryn
AU - Campbell, Patrick
AU - Cashman, Lisa
AU - Chavala, Susmita
AU - Daw, Jessica
AU - Dawley, Nicole
AU - Deguzman, Lynn
AU - Gascho, Eric
AU - Goldstein, Fred
AU - Graff, Jennifer
AU - Hagan, Angela
AU - Hoffman, Dorothy
AU - Jeffrey, Paul
AU - Jhawar, Sharon
AU - Kogut, Stephen
AU - Kountz, David
AU - Leal, Sandra
AU - Gette, Lisa Le
AU - Lehman, Brian
AU - Lyles-Stolz, Lauren
AU - Mcrae, Jacquelyn
AU - Modi, Bhavesh
AU - Ndehi, Lilian
AU - Pizzi, Laura
AU - Powell, Bryan
AU - Powell, Lauren
AU - Reddy, Prabashni
AU - Reddy, Vimal
AU - Schlaifer, Marissa
AU - Schuster, Annie
AU - Suther, Tim
AU - Wartman, Gretchen C.
AU - Winiarek, Claire Wulf
AU - Dharbhamalla, Vyishali
N1 - Funding Information:
This forum was sponsored by Amgen, the National Pharmaceutical Council, Pfizer, PhRMA, Sandoz, and Takeda. Their representatives joined the forum as panelists or participants. These proceedings were prepared as a summary of the forum to represent common themes; they are not necessarily endorsed by all attendees nor should they be construed as reflecting group consensus.
Publisher Copyright:
Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - As part of its stand against racial injustice and its commitment to action, AMCP dedicated a partnership forum to discussion of potential sources of racial health disparities and inequities in benefit design because these are primary drivers of medication use. This forum, held virtually March 23-24, 2021, convened more than 40 experts representing key stakeholders from managed care settings. Key principles that emerged from the forum discussion as means to mitigate racial health disparities were to acknowledge that structural racism exists and that it can impact the provision of health care, including but not limited to formulary development and benefit design processes; to integrate proactive strategies to improve equity, beginning with education and training, into all aspects of health care; and to view patients holistically with an understanding of the compounding effect of social determinants of health on their personal wellness. With these principles in mind, participants highlighted several priority considerations including improving existing gaps in data, addressing diversity and equity as they relate to formulary development, evaluating systems such as benefit offerings through a lens of increasing equity, recognizing cost-related factors that affect equity, considering patients' interactions with and their ability to access the system, and committing to patient-centered care. Participants also suggested areas for policy-related focus and noted the need to develop and deploy specific education and training.
AB - As part of its stand against racial injustice and its commitment to action, AMCP dedicated a partnership forum to discussion of potential sources of racial health disparities and inequities in benefit design because these are primary drivers of medication use. This forum, held virtually March 23-24, 2021, convened more than 40 experts representing key stakeholders from managed care settings. Key principles that emerged from the forum discussion as means to mitigate racial health disparities were to acknowledge that structural racism exists and that it can impact the provision of health care, including but not limited to formulary development and benefit design processes; to integrate proactive strategies to improve equity, beginning with education and training, into all aspects of health care; and to view patients holistically with an understanding of the compounding effect of social determinants of health on their personal wellness. With these principles in mind, participants highlighted several priority considerations including improving existing gaps in data, addressing diversity and equity as they relate to formulary development, evaluating systems such as benefit offerings through a lens of increasing equity, recognizing cost-related factors that affect equity, considering patients' interactions with and their ability to access the system, and committing to patient-centered care. Participants also suggested areas for policy-related focus and noted the need to develop and deploy specific education and training.
UR - http://www.scopus.com/inward/record.url?scp=85122972915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122972915&partnerID=8YFLogxK
U2 - 10.18553/JMCP.2021.21217
DO - 10.18553/JMCP.2021.21217
M3 - Article
C2 - 34597158
AN - SCOPUS:85122972915
SN - 2376-0540
VL - 28
SP - 125
EP - 131
JO - Journal of managed care & specialty pharmacy
JF - Journal of managed care & specialty pharmacy
IS - 1
ER -